Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Strata Critical Medical (SRTA) Shares Outstanding (Weighted Average) (2019 - 2025)

Strata Critical Medical (SRTA) has disclosed Shares Outstanding (Weighted Average) for 7 consecutive years, with $82.1 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Weighted Average) rose 5.93% to $82.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $82.1 million through Dec 2025, up 5.93% year-over-year, with the annual reading at $82.1 million for FY2025, 5.93% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $82.1 million at Strata Critical Medical, up from $81.2 million in the prior quarter.
  • The five-year high for Shares Outstanding (Weighted Average) was $82.1 million in Q4 2025, with the low at $26.1 million in Q1 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $69.3 million, with a median of $73.1 million recorded in 2023.
  • The sharpest move saw Shares Outstanding (Weighted Average) surged 620.27% in 2021, then rose 1.72% in 2023.
  • Over 5 years, Shares Outstanding (Weighted Average) stood at $69.8 million in 2021, then rose by 2.12% to $71.2 million in 2022, then rose by 3.21% to $73.5 million in 2023, then grew by 5.41% to $77.5 million in 2024, then grew by 5.93% to $82.1 million in 2025.
  • According to Business Quant data, Shares Outstanding (Weighted Average) over the past three periods came in at $82.1 million, $81.2 million, and $80.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.